Please assess the completion status of the following clinical trial:

Trial Title: Pain, Agitation and Delirium (PAD) Protocol in the Duke CICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients admitted to the Duke CICU, who require intubation and sedation for mechanical ventilation that is expected to be \>24 hours in duration will be included, unless they meet the specified exclusion criteria.~* Patients intubated within one hour prior to care transition to the CICU will also be screened for inclusion.~Exclusion Criteria:~* Exclusion criteria include patients following resuscitation from cardiac arrest who are treated on the cooling protocol~* patients who have suffered a neurologic event (seizure, stroke) or who have baseline dementia, both of which could limit delirium assessment~* patients with child class B and C liver disease~* patients with known allergy to study medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Midazolam (Type: ACTIVE_COMPARATOR): IV midazolam will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
- Propofol or Dexmedetomidine (Type: ACTIVE_COMPARATOR): Propofol or Dexmedetomidine per physician discretion will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).